Licensing status

Publication and contact information


Transient receptor potential cation channel subfamily C member 5 (TRPC5)-containing extracellular vesicles as a marker of chemotherapy resistance in breast cancer

Studies in patient samples, mice and cell culture suggest TRPC5-containing extracellular vesicles could help predict chemotherapy resistance in breast cancer. In coculture of chemoresistant and chemosensitive human breast cancer cell lines, TRPC5-containing extracellular vesicles were shown to enter chemosensitive cells and increase their resistance to chemotherapy. In cell culture and a mouse xenograft model of chemoresistant human breast cancer, siRNA against TRPC5 decreased the release of TRPC5-containing extracellular vesicles compared with scrambled siRNA. In samples from 26 patients with breast cancer who received anthracycline- and taxane-based chemotherapy, samples from patients with a complete or partial response had lower TRPC5 expression than those from patients with progressive or stable disease. Next steps include validating TRPC5-containing vesicles as a biomarker of chemotherapy response and developing a quantitative assay for TRPC5-containing vesicles in peripheral blood.

SciBX 7(18); doi:10.1038/scibx.2014.543
Published online May 8, 2014

Patented; available for licensing from Jiangnan University
Contact: Zheng Jing, Jiangnan University, Wuxi, China

Ma, X. et al. Proc. Natl. Acad. Sci. USA; published online April 14, 2014;
Contact: Jian Jin, Jiangnan University, Wuxi, China
Contact: Xin Ma, same affiliation as above